Sareum Announces Second Collaboration with H. Lundbeck

Sareum Holdings plc has announced that it has entered into a second collaborative agreement with H. Lundbeck A/S to provide protein structure determination capabilities to accelerate drug discovery research at Lundbeck.

Under the terms of this 12 month agreement, Sareum will apply its skills in high throughput protein expression, purification and structure determination to assist Lundbeck’s scientists in developing improved therapeutics to help patients suffering from diseases of the central nervous system, Lundbeck’s key drug discovery focus area.

In return, Sareum will receive research fees and success milestone payments.

Commenting on the agreement, Sareum’s Chief Executive Officer, Dr Tim Mitchell, said, "We are very pleased that Lundbeck have chosen to broaden their collaboration with Sareum."

"Developing longer term relationships with important customers such as Lundbeck is a key component of our business strategy and further evidence of our success in being a partner of choice for structure-based drug discovery."

Commenting on the agreement, Lundbeck’s Vice President of Research DK, Dr. Klaus Peter Bogeso, said, "Structure-based drug design is an important part of a modern drug discovery strategy, and we look forward to using this broadened collaboration with Sareum to enhance the success of our Drug Discovery process."

"The partnership also further illustrates Lundbeck’s commitment to accelerating the discovery of novel therapies for patients suffering from neurological and psychiatric diseases."